ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV) today announced the appointment of Dr. Brian Levy to its Board of Directors. Dr. Levy brings more than three decades of industry expertise in the development of successful ophthalmic therapeutics. He is currently the Chief Scientific Officer of Nexis Vision, which is developing a novel refractive surgery technology. Previously, he was the Chief Operating Officer of Danube Pharmaceuticals, a company developing therapeutics for the treatment of glaucoma. Prior to that, Dr. Levy was at Bausch & Lomb where he held a series of senior leadership positions, most recently serving as Corporate Vice President and Chief Medical Officer responsible for preclinical, clinical and medical affairs for all Bausch & Lomb businesses worldwide. Among his many accomplishments, he oversaw the development of Besivance®, which is an InSite Vision-licensed drug. Dr. Levy is also a Clinical Professor of Ophthalmology at the University of Rochester in New York. He earned a Doctor of Optometry degree from the University of California, Berkeley in 1976.
